A Two-Arm, Multi-Center Trial of Revlimid and Rituximab, for First-Line Treatment in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL).
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Lenalidomide; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Dec 2011 Results were presented at the 53rd Annual Meeting of the American Society of Hematology (ASH)
- 13 Dec 2011 Status changed from recruiting to completed.